

REGULATORY INFORMATION DISTRIBUTION SYSTEM (RIDS)

ACCESSION NBR: 8408280220 DOC. DATE: 84/08/23 NOTARIZED: YES DOCKET #
 FACIL: 50-260 Browns Ferry Nuclear Power Station, Unit 2, Tennessee 05000260
 AUTH. NAME AUTHOR AFFILIATION
 MILLS, L.M. Tennessee Valley Authority
 RECIP. NAME RECIPIENT AFFILIATION
 DENTON, H.R. Office of Nuclear Reactor Regulation, Director

SUBJECT: Application for amdn to License DPR-52, changing Tech Specs to accommodate Unit 2, Cycle 6 operation & reflecting plant mods to be performed during refueling outage.

"See Tech Specs" 3 ENCL 40 SIZE: 3+91
 DISTRIBUTION CODE: A001D COPIES RECEIVED: LTR 3 ENCL 40
 TITLE: OR Submittal: General Distribution

NOTES: NMSS/FCAF 1cy. 1cy NMSS/FCAF/PM. 05000260
 OL: 06/28/74

RECIPIENT ID CODE/NAME	COPIES LTTR ENCL	RECIPIENT ID CODE/NAME	COPIES LTTR ENCL
NRR ORB2 BC 01.	7 7		
INTERNAL: ADM/LFMB	1 0	ELD/HDS4	1 0
NRR/DE/MTB	1 1	NRR/DL DIR	1 1
NRR/DL/ORAB	1 0	NRR/DSI/METB	1 1
NRR/DSI/RAB	1 1	REG FILE 04	1 1
RGN2	1 1		
EXTERNAL: ACRS 09	6 6	LPDR 03	1 1
NRC PDR 02	1 1	NSIC 05	1 1
NTIS	1 1		

NOTES: 2 2
 W/Check \$150.00 #22635

Add: NRR/DHFS DEP4
 NRR/DHFS/DIR
 NRR/DHFS/PSRB
 RGN2/DRSS/EPRPB
 RM/DDAMI/MIB

TOTAL NUMBER OF COPIES REQUIRED: LTTR

33 30
 28 ENCL 25

Y
[Illegible text block]

[Illegible text block]

TENNESSEE VALLEY AUTHORITY

CHATTANOOGA, TENNESSEE 37401

400 Chestnut Street Tower II

August 23, 1984

TVA BFNP TS 199

Mr. Harold R. Denton, Director
Office of Nuclear Reactor Regulation
U.S. Nuclear Regulatory Commission
Washington, D.C. 20555

Dear Mr. Denton:

In the Matter of the)
Tennessee Valley Authority)

Docket No. 50-260

In accordance with the provisions of 10 CFR Parts 50.59 and 50.90, we are enclosing 40 copies of a requested amendment to license DPR-52, to change the technical specifications of Browns Ferry Nuclear Plant unit 2 (enclosure 1). The enclosed technical specifications are needed to accommodate unit 2 cycle 6 operation and to reflect plant modifications to be performed during the refueling outage.

Description and justification for the proposed changes are provided as enclosure 2. Included in the description is General Electric report "Bottled-up Operation of a BWR," NEDO-20697, dated November 1974. Also included is the reload licensing report for unit 2 cycle 6 documenting core loading and analyses performed, TVA-RLR-002.

In accordance with 10 CFR 50.91(a)(1) the determination of no significant hazards consideration is provided as enclosure 3.

The enclosed technical specification revisions are being reviewed concurrently by the Browns Ferry Nuclear Safety Review Board.

Browns Ferry unit 2 is scheduled to complete the cycle 5 outage and to start cycle 6 operation in early January 1985. We, therefore, request NRC staff approval of the enclosed license amendment request by December 18, 1984.

Enclosed is a check for the \$150 amendment fees required by 10 CFR Part 170.12.

Very truly yours,

TENNESSEE VALLEY AUTHORITY

L. M. Mills
L. M. Mills, Manager
Nuclear Licensing

	Ltr	Encl
Add: NRR/DHFS DEAF	1	1
NRR/DHFS/DIR	1	1
NRR/DHFS/PSRB	1	1
NRR/DSI/CPB	1	1
Rgn 2/DRSS/EPRPB	1	1
Rm/DOAMI/MLB	1	1

Subscribed and sworn to before
me this 23rd day of Aug. 1984.

Paulette H. White
Notary Public
My Commission Expires 9-5-84

A001
S/Ad
w/ check \$150.00
22635

Enclosures

cc: See page 2

An Equal Opportunity Employer

8408280220 840823
PDR ADDCK 05000260
PDR

Mr. Harold R. Denton

August 23, 1984

cc (Enclosures):

Mr. Charles R. Christopher
Chairman, Limestone County Commission
P.O. Box 188
Athens, Alabama 35611

Dr. Ira L. Myers
State Health Officer
State Department of Public Health
State Office Building
Montgomery, Alabama 36104

Mr. R. J. Clark
Browns Ferry Project Manager
U.S. Nuclear Regulatory Commission
7920 Norfolk Avenue
Bethesda, Maryland 20814

[illegible][illegible]

1. *Pharmaceuticals*—The pharmaceutical industry is a major contributor to the U.S. economy, with sales of over \$100 billion in 1990. The industry is highly competitive, with many firms vying for market share. The industry is also highly regulated, with the FDA overseeing the safety and efficacy of drugs. The industry is also highly innovative, with many new drugs being developed each year.